File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Book Chapter: Antiobesity drugs for obese women planning pregnancy

TitleAntiobesity drugs for obese women planning pregnancy
Authors
Li, RHWLam, KSLHo, PC
KeywordsAntiobesity drugs
prepregnancy
orlistat
lorcaserin
phentermine/topiramate
Issue Date2020
PublisherElsevier
Citation
Antiobesity drugs for obese women planning pregnancy. In Mahmood, TA; Arulkumara, S & Chervenak, FA (Eds.), Obesity and Obstetrics (2nd ed.), p. 301-306. Amsterdam: Elsevier, 2020 How to Cite?
DOI: http://dx.doi.org/10.1016/B978-0-12-817921-5.00030-8
AbstractObesity remains an important risk factor for women planning for pregnancy because of its adverse effects on reproductive outcome. In individuals who experience difficulty in reducing significant weight with lifestyle intervention alone, the use of antiobesity drugs can be an adjunct. Orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, liraglutide, and metformin are the options currently. However, these weight-loss interventions should precede any planned conception or fertility treatment.
DescriptionChapter 30
Persistent Identifierhttp://hdl.handle.net/10722/305658
ISBN
9780128179215

 

DC FieldValueLanguage
dc.contributor.authorLi, RHW-
dc.contributor.authorLam, KSL-
dc.contributor.authorHo, PC-
dc.date.accessioned2021-10-20T10:12:30Z-
dc.date.available2021-10-20T10:12:30Z-
dc.date.issued2020-
dc.identifier.citationAntiobesity drugs for obese women planning pregnancy. In Mahmood, TA; Arulkumara, S & Chervenak, FA (Eds.), Obesity and Obstetrics (2nd ed.), p. 301-306. Amsterdam: Elsevier, 2020-
dc.identifier.isbn9780128179215-
dc.identifier.urihttp://hdl.handle.net/10722/305658-
dc.descriptionChapter 30-
dc.description.abstractObesity remains an important risk factor for women planning for pregnancy because of its adverse effects on reproductive outcome. In individuals who experience difficulty in reducing significant weight with lifestyle intervention alone, the use of antiobesity drugs can be an adjunct. Orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, liraglutide, and metformin are the options currently. However, these weight-loss interventions should precede any planned conception or fertility treatment.-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofObesity and Obstetrics (2nd ed.)-
dc.subjectAntiobesity drugs-
dc.subjectprepregnancy-
dc.subjectorlistat-
dc.subjectlorcaserin-
dc.subjectphentermine/topiramate-
dc.titleAntiobesity drugs for obese women planning pregnancy-
dc.typeBook_Chapter-
dc.identifier.emailLi, RHW: raymondli@hku.hk-
dc.identifier.emailLam, KSL: ksllam@hku.hk-
dc.identifier.emailHo, PC: pcho@HKUCC-COM.hku.hk-
dc.identifier.authorityLi, RHW=rp01649-
dc.identifier.authorityLam, KSL=rp00343-
dc.identifier.authorityHo, PC=rp00325-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/B978-0-12-817921-5.00030-8-
dc.identifier.hkuros326629-
dc.identifier.spage301-
dc.identifier.epage306-
dc.publisher.placeAmsterdam-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats